These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19060597)

  • 1. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
    Greenberg S; Rugo HS
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment options in triple negative breast cancer.
    Rodler E; Korde L; Gralow J
    Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer: novel therapies and new directions.
    Pal SK; Mortimer J
    Maturitas; 2009 Aug; 63(4):269-74. PubMed ID: 19632796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials in triple negative breast cancer.
    Reeder-Hayes KE; Carey LA; Sikov WM
    Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
    Burness ML; Grushko TA; Olopade OI
    Cancer J; 2010; 16(1):23-32. PubMed ID: 20164687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of triple negative breast cancer.
    Oakman C; Viale G; Di Leo A
    Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
    De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates in the treatment of basal/triple-negative breast cancer.
    Shastry M; Yardley DA
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?
    Siziopikou KP; Ariga R; Proussaloglou KE; Gattuso P; Cobleigh M
    Breast J; 2006; 12(4):360-2. PubMed ID: 16848847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
    Montemurro F; Aglietta M
    Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer: role of antiangiogenic agents.
    Greenberg S; Rugo HS
    Cancer J; 2010; 16(1):33-8. PubMed ID: 20164688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.